

# EXAM OF FOCUS – FEMALE PELVIS PROTOCOL

JANUARY 2024

[CLICK TO READ AND REVIEW THE FULL PELVIC PROTOCOL HERE](#)

For our January Exam of Focus, the team reviewed our pelvic protocol. You will be happy to hear that we did not make any changes to the required images! We will however be starting to use the ORADS classification system for adnexal and ovarian masses. We have discussed this in a recent lecture, but please be sure to read more about ORADS in the protocol and sections below. I have already changed Viewpoint to align with the ORADS lexicon, so you may notice the options to choose for describing ovarian masses looks different. Also, although we are not changing the image requirements, I know we have had a number of additions over the course of year, so I would like to make sure to highlight these for you in case there was anything missed! I will also include a few things that continue to be questioned amongst staff. Hope this helps to clarify most things, but as always, reach out if you have additional questions!

## BILLING AND GENERAL INFO:

- Only use sterile gel packs for the transvaginal exams. Never use a previously opened one or the gel we use for TV exams.
- Patients do not need to have a full bladder unless we are only scanning abdominally.
- Remember to include the LMP in the indication portion of the report, if postmenopausal, state this instead.
- If a patient has had a hysterectomy or ovary removed, you cannot charge a UPELTV. You must change it to a UPELL and UTVAG.
- The required transabdominal images were decreased in March 2023. Review what is required if you are still doing a full duplication of images. Fewer serial images of the structures are needed.
- If you do dopplers or 3D images, be sure to charge for these and put it in the method section of the report.

**ENDOMETRIAL ADHESION EVALUATION:** The following should be performed on patients with chronic pain or if endometriosis is suspected.

- Transverse cine sweep through the entire cervix to show uterosacral ligaments. It can be included in your transverse uterus sweep, or a separate sweep if needed. Either way, you need to scan **completely** through the cervix. A lot of the sweeps we have been getting have not extended all the way through the cervix to show the ligaments. Be aware that this can often be tender for the patient, especially if adhesions are present, so letting them know in advance that it may be uncomfortable is best.
- Sliding sign: To perform the sliding sign, position the probe in the posterior fornix and then push against the rectum to see if the rectum moves free of the posterior cervix/uterus. Do not just push straight into the cervix, you must be **posterior** to the cervix to produce the movement needed. If the patient cannot tolerate the pressure required for the vaginal sliding sign, you can also try to manually press on the fundus of the uterus from the top of the abdomen with your non-scanning hand. This should also result in creating the motion needed to show whether the uterus moves independently from the bowel.

## UTERUS:

- The uterine length should still be measured **without** the cervix included. Normal uterine corpus volume without the cervix is less than 80cc.
- Your sagittal sweep of the uterus on transabdominal imaging should be done with the depth set deep enough to visualize the posterior cul de sac and wide enough to see superior to the uterine fundus. Not doing this has resulted in missed pedunculated fibroids and other pathology.
- We are using new IUD location descriptions to better align with what the gyn providers use -
  - “Fundal” if normal location
  - “Non-fundal” if low in cavity
  - “Embedded” if within myometrium
  - “Partially expelled” if within cervix
- 3D images are required if interstitial/cornual ectopic is suspected.



## ADNEXA:

- The protocol includes sweeps and still images of the adnexa in both planes. Ovarian sweeps are not required unless pathology is present.
- Additional sweeps of the adnexa **with and without** color are required if evaluating for ectopic pregnancy.

**OVARIES:**

- Ovarian volumes are subjective. The radiologist will determine whether they are enlarged given the patient situation. For the purposes of PCOS, the volume is considered increased if over 10cc.
- Ovaries should be measured with 2 measurements in long axis, one in transverse. You should measure the ovary length in its longest dimension first and then 90 degrees to that for the height. Your width measurement will be more straight across in a coronal plane, or a bit oblique if sits at an angle. See example below.
- Normal left ovary measured in three orthogonal planes.

**Do not measure it like this (in red):**



© Association for medical ultrasound

**ORADS v2022:**

- In order to align with the newest version of the ORADS classification system, we will be using the below descriptions for adnexal and ovarian lesions. These options have all been added to Viewpoint. Do not just say “complex cyst.” Use these descriptors as needed to explain why it is complex. If it is a “Unilocular, simple anechoic cyst” you can just say that and leave out the rest of the descriptions, but all complex cysts should include each relevant option below. The radiologist will assign the ORADS score based on our description, but in order for them to choose the correct one, they need our description to be as complete as possible.
  - **Unilocular, bilocular, or multilocular**
  - **Solid vs cystic** (Solid lesion = >80% solid)
  - **Septations**
  - **Solid components** -Solid component = protrudes >3mm into cyst lumen from wall or septation. A papillary projection (pp) is a type of solid component that is surrounded by fluid on three sides. The number of papillary projections is also important for risk stratification, >4 pp is high risk.
  - **Calcifications**
  - **Shadowing** -must be diffuse or broad shadowing
  - **Smooth or irregular wall** -evaluate the inner wall if cystic, outer wall if solid
  - **Color flow** – only comment whether present or not present.
  - (Radiologists will choose the color score:
    - CS 1 – No Flow
    - CS 2 – Minimal Flow
    - CS 3 – Moderate Flow
    - CS 4 – Very Strong Flow)




Fig. 6—Schematic shows color score (CS) grading system of degree of internal vascularity within lesion used for risk stratification of solid lesions with smooth outer contour, multilocular cystic lesions with smooth inner walls and septation, and multilocular cystic lesions with solid components. Tips to ensure accurate interpretation of CS include using an adjacent structure (e.g., uterus or contralateral ovary) and optimizing baseline settings. CS 1 reflects no detectable flow. CS 2 should be rendered when flow is present, albeit challenging to see. CS 4 reflects robust flow that is easily seen. Anything between these two should be categorized as moderate flow, CS 3.

The ORADS publications and charts can be found below, but the protocol and our website has them should you need to reference them in the future. The links can be found on our website under the Guidelines & Reference Values tab, in the pelvic folder: [PELVIC US GUIDELINES](#)

**[DON'T FORGET TO READ AND REVIEW THE FULL PELVIC PROTOCOL HERE](#)**



| O-RADS Score  | Risk Category [IOTA Model]         | Lexicon Descriptors   |  | Management  |                            |
|---|------------------------------------|---|--|---|----------------------------|
|   |                                    |   |  | Pre-menopausal  | Post-Menopausal            |
| 0   | Incomplete Evaluation [N/A]        | Lesion features relevant for risk stratification cannot be accurately characterized due to technical factors          |  | Repeat US study or MRI  |                            |
| 1   | Normal Ovary [N/A]                 | No ovarian lesion<br>Physiologic cyst: follicle (≤3 cm) or corpus luteum (typically ≤3 cm)                            |  | None  |                            |
| 2   | Almost Certainly Benign [ $<1\%$ ] | Simple cyst   | ≤3 cm  | N/A (see follicle)  | None                       |
|   |                                    |   | >3 cm to 5 cm  | None  | Follow-up US in 12 months* |
|   |                                    |   | >5 cm but <10 cm   | Follow-up US in 12 months*  | Follow-up US in 12 months* |
|   |                                    | Unilocular, smooth, non-simple cyst (internal echoes and/or incomplete septations)<br>-----<br>Bilocular, smooth cyst | ≤3 cm  | None  | Follow-up US in 12 months* |
|   |                                    |   | >3 cm but <10 cm   | Follow-up US in 6 months*   |                            |
| Typical benign ovarian lesion (see "Classic Benign Lesions" table)<br>Typical benign extraovarian lesion (see "Classic Benign Lesions" table) | <10 cm<br>Any size                 | See "Classic Benign Lesions" table for descriptors and management   |  |   |                            |
| 3   | Low Risk [1 – <10%]                | Typical benign ovarian lesion (see "Classic Benign Lesions" table), ≥10 cm  |  | Imaging:<br>• If not surgically excised, consider follow-up US within 6 months**<br>• If solid, may consider US specialist (if available) <u>or</u> MRI (with O-RADS MRI score)†<br>Clinical: Gynecologist  |                            |
|   |                                    | Uni- or bilocular cyst, smooth, ≥10 cm  |  |   |                            |
|   |                                    | Unilocular cyst, irregular, any size  |  |   |                            |
|   |                                    | Multilocular cyst, smooth, <10 cm, CS <4  |  |   |                            |
|   |                                    | Solid lesion, ± shadowing, smooth, any size, CS = 1   |  |   |                            |
| Solid lesion, shadowing, smooth, any size, CS 2–3   |                                    |   |  |   |                            |
| 4   | Intermediate Risk [10 – <50%]      | Bilocular cyst without solid component(s)   | Irregular, any size, any CS                                | Imaging:<br>Options include:<br>• US specialist (if available) <u>or</u><br>• MRI (with O-RADS MRI score)† <u>or</u><br>• Per gyn-oncologist protocol<br>Clinical: Gynecologist with gyn-oncologist consultation <u>or</u> solely by gyn-oncologist |                            |
|   |                                    | Multilocular cyst without solid component(s)  | Smooth, ≥10 cm, CS <4                                      |   |                            |
|   |                                    |   | Smooth, any size, CS 4                                     |   |                            |
|   |                                    | Unilocular cyst with solid component(s)   | Irregular, any size, any CS                                |   |                            |
|   |                                    |   | <4 pps or solid component(s) not considered a pp; any size |   |                            |
| Bi- or multilocular cyst with solid component(s)  | Any size, CS 1–2                   |   |  |   |                            |
| Solid lesion, non-shadowing   | Smooth, any size, CS 2–3           |   |  |   |                            |
| 5   | High Risk [≥50%]                   | Unilocular cyst, ≥4 pps, any size, any CS   |  | Imaging: Per gyn-oncologist protocol<br>Clinical: Gyn-oncologist  |                            |
|   |                                    | Bi- or multilocular cyst with solid component(s), any size, CS 3–4  |  |   |                            |
|   |                                    | Solid lesion, ± shadowing, smooth, any size, CS 4   |  |   |                            |
|   |                                    | Solid lesion, irregular, any size, any CS   |  |   |                            |
| Ascites and/or peritoneal nodules††   |                                    |   |  |   |                            |

**GLOSSARY**

|   |  |
|---|--|
| Smooth and irregular: refer to <b>inner</b> walls/septation(s) for <b>cystic</b> lesions, and <b>outer</b> contour for <b>solid</b> lesions; irregular inner wall for cysts = <3 mm in height | Solid: excludes blood products and dermoid contents; solid lesion = ≥80% solid; solid component = protrudes ≥3 mm (height) into cyst lumen off wall or septation |
| Shadowing: must be diffuse or broad to qualify; excludes refractive artifact  | pp = papillary projection; subtype of solid component surrounded by fluid on 3 sides   |
| CS = color score; degree of intralosomal vascularity; 1 = none, 2 = minimal flow, 3 = moderate flow, 4 = very strong flow   | Bilocular = 2 locules; multilocular = ≥3 locules; bilocular smooth cysts have a lower risk of malignancy, regardless of size or CS                               |
| Postmenopausal = ≥1 year amenorrhea (early: <5 yrs; late: ≥5 yrs); if uncertain or uterus surgically absent, use age >50 years (early = >50 yrs but <55 yrs, late = ≥55 yrs)                  |  |

\*Shorter imaging follow-up may be considered in some scenarios (eg, clinical factors). If smaller (≥10–15% decrease in average linear dimension), no further surveillance. If stable, follow-up US at 24 months from initial exam. If enlarging (≥10–15% increase in average linear dimension), consider follow-up US at 12 and 24 months from initial exam, then management per gynecology. For changing morphology, reassess using lexicon descriptors. **Clinical management with gynecology as needed.**

\*\*There is a paucity of evidence for defining the optimal duration or interval for imaging surveillance. Shorter follow-up may be considered in some scenarios (eg, clinical factors). If stable, follow-up at 12 and 24 months from initial exam, then as clinically indicated. For changing morphology, reassess using lexicon descriptors.

† MRI with contrast has higher specificity for solid lesions, and cystic lesions with solid component(s).

†† Not due to other malignant or non-malignant etiologies; specifically, must consider other etiologies of ascites in categories 1–2.

| Lesion  | Descriptors and Definitions<br>For any atypical features on initial or follow-up exam, use other lexicon descriptors (eg, unilocular, multilocular, solid, etc.)  | Management<br>If sonographic features are only suggestive, and overall assessment is uncertain, consider follow-up US within 3 months   |
|---|---|---|
| <p><b>Typical Hemorrhagic Cyst</b></p>          | <p>Unilocular cyst, <b>no internal vascularity*</b>, and at least <u>one</u> of the following:</p> <ul style="list-style-type: none"> <li>• Reticular pattern (fine, thin intersecting lines representing fibrin strands)</li> <li>• Retractable clot (intracystic component with straight, concave, or angular margins)</li> </ul> | <p>Imaging:</p> <ul style="list-style-type: none"> <li>○ Premenopausal: <ul style="list-style-type: none"> <li>• ≤5 cm: None</li> <li>• &gt;5 cm but &lt;10 cm: Follow-up US in 2–3 months</li> </ul> </li> <li>○ Early postmenopausal (&lt;5 years): <ul style="list-style-type: none"> <li>• &lt;10 cm, options to confirm include: <ul style="list-style-type: none"> <li>▪ Follow-up US in 2–3 months <u>or</u></li> <li>▪ US specialist (if available) <u>or</u></li> <li>▪ MRI (with O-RADS MRI score)</li> </ul> </li> </ul> </li> <li>○ Late postmenopausal (≥5 years): <ul style="list-style-type: none"> <li>• Should not occur; recategorize using other lexicon descriptors.</li> </ul> </li> </ul> <p>Clinical: Gynecologist**</p> |
| <p><b>Typical Dermoid Cyst</b></p>              | <p>Cystic lesion with ≤3 locules, <b>no internal vascularity*</b>, and at least <u>one</u> of the following:</p> <ul style="list-style-type: none"> <li>• Hyperechoic component(s) (diffuse or regional) with shadowing</li> <li>• Hyperechoic lines and dots</li> <li>• Floating echogenic spherical structures</li> </ul>         | <p>Imaging:</p> <ul style="list-style-type: none"> <li>○ ≤3 cm: May consider follow-up US in 12 months†</li> <li>○ &gt;3 cm but &lt;10 cm: If not surgically excised, follow-up US in 12 months†</li> </ul> <p>Clinical: Gynecologist**</p>   |
| <p><b>Typical Endometrioma</b></p>              | <p>Cystic lesion with ≤3 locules, <b>no internal vascularity*</b>, homogeneous low-level/ground glass echoes, and smooth inner walls/septation(s)</p> <ul style="list-style-type: none"> <li>• ± Peripheral punctate echogenic foci in wall</li> </ul>  | <p>Imaging:</p> <ul style="list-style-type: none"> <li>○ Premenopausal: <ul style="list-style-type: none"> <li>• &lt;10 cm: If not surgically excised, follow-up US in 12 months†</li> </ul> </li> <li>○ Postmenopausal: <ul style="list-style-type: none"> <li>• &lt;10 cm <u>and initial exam</u>, options to confirm include <ul style="list-style-type: none"> <li>▪ Follow-up US in 2–3 months <u>or</u></li> <li>▪ US specialist (if available) <u>or</u></li> <li>▪ MRI (with O-RADS MRI score)</li> </ul> </li> </ul> </li> </ul> <p>Then, if not surgically excised, recommend follow-up US in 12 months†</p> <p>Clinical: Gynecologist**</p>  |
| <p><b>Typical Paraovarian Cyst</b></p>          | <p>Simple cyst separate from the ovary</p>  | <p>Imaging: None<br/>Clinical: Gynecologist**</p>   |
| <p><b>Typical Peritoneal Inclusion Cyst</b></p> | <p>Fluid collection with ovary at margin or suspended within that conforms to adjacent pelvic organs</p> <ul style="list-style-type: none"> <li>• ± Septations (representing adhesions)</li> </ul>  | <p>Imaging: None<br/>Clinical: Gynecologist**</p>   |
| <p><b>Typical Hydrosalpinx</b></p>              | <p>Anechoic, fluid-filled tubular structure</p> <ul style="list-style-type: none"> <li>• ± Incomplete septation(s) (representing folds)</li> <li>• ± Endosalpingeal folds (short, round projections around inner walls)</li> </ul>  | <p>Imaging: None<br/>Clinical: Gynecologist**</p>   |

\*Excludes vascularity in walls or intervening septation(s)

\*\*As needed for management of clinical issues

† There is a paucity of evidence for defining the need, optimal duration or interval of timing for surveillance. If stable, consider US follow-up at 24 months from initial exam, then as clinically indicated. Specifically, evidence does support **an increased risk of malignancy in endometriomas following menopause and those present greater than 10 years.**



**O-RADS™ Ultrasound v2022 Lexicon Categories, Terms, and Definitions**  
Revised: January 2023

| Term   | Sub-term                   | Definition   | Comments  |
|--|----------------------------|--|---|
| <b>Major Categories of Imaging Findings</b>            |                            |  |   |
| <b>Physiologic (consistent with normal physiology)</b> |                            |  |   |
| Follicle   |                            | Simple cyst (unilocular, anechoic, smooth) $\leq 3$ cm in premenopausal group  |   |
| Corpus Luteum (CL)                                     |                            | Thick-walled cyst <b>typically</b> $\leq 3$ cm, $\pm$ crenulated inner walls, $\pm$ internal echoes, with peripheral flow in premenopausal group | - May be solid-appearing (no visible central fluid) with peripheral flow<br>- No internal flow  |
| <b>Lesion (not physiologic)</b>                        |                            |  |   |
| Unilocular cyst  | Without solid component(s) | Cystic lesion with a single locule (no complete septa)   | - $\pm$ internal echoes, incomplete septa, wall irregularity $< 3$ mm in height<br><br>- <b>Simple cyst:</b> anechoic and smooth inner walls<br><br>- <b>Non-simple cyst:</b> smooth inner walls and internal echoes or incomplete septa                          |
|  | With solid component(s)    | As above and includes solid tissue $\geq 3$ mm in height   |   |
| Bilocular cyst   | Without solid component(s) | Cystic lesion with 2 locules (single complete septation)   | $\pm$ internal echoes, incomplete septa, or wall/septal irregularity ( $< 3$ mm height)   |
|  | With solid component(s)    | As above and includes solid tissue $\geq 3$ mm in height   |   |
| Multilocular cyst                                      | Without solid component(s) | Cystic lesion with $\geq 3$ locules ( $\geq 2$ complete septations)  | $\pm$ internal echoes, incomplete septa, or wall/septal irregularity ( $< 3$ mm in height)  |
|  | With solid component(s)    | As above and includes solid tissue $\geq 3$ mm in height   |   |
| Solid ( $\geq 80\%$ )                                  |                            | Lesion with at least 80% solid tissue (based on echogenicity and echotexture)  | - $\pm$ internal vascularity<br>- May use term <b>solid-appearing</b> if no internal vascularity  |
| <b>Size</b>  |                            |  |   |
| Maximum diameter                                       |                            | Largest diameter regardless of the plane in which it is obtained   | Used for risk stratification  |
| Average linear dimension                               |                            | (Maximum length + height + width)/3  | Used to assess interval change  |
| <b>Solid or Solid-Appearing Lesions</b>                |                            |  |   |
| <b>External Contour</b>                                |                            |  |   |
| Smooth   |                            | Uniform/even outer margin  |   |
| Irregular  |                            | Non-uniform/uneven outer margin  | Includes lobulated  |
| <b>Posterior Acoustic Features</b>                     |                            |  |   |
| Shadowing  |                            | <b>Broad or diffuse</b> hypoechogenicity posterior to a lesion due to sound attenuation  | - Associated with calcifications and fibromatous lesions<br>- Relevant for solid smooth<br>- <b>Differs from refractive artifact</b> due to differences in attenuation by adjacent tissues, typically seen as linear shadowing from within or at edge of a lesion |
| <b>Cystic Lesions</b>                                  |                            |  |   |
| <b>Inner Walls or Septations</b>                       |                            |  |   |

|   |  |   |   |
|---|--|---|---|
| Smooth                                    |  | Uniform/even inner margin or septation  |   |
| Irregular                                 |  | Non-uniform/uneven inner margin or septation  | Focal wall or septal thickening < 3 mm in height  |
| Calcifications                            |  | High-level echogenicity within wall associated with posterior shadowing   | Risk assessment based upon smooth or irregular margin   |
| <b>Internal Content</b>                   |  |   |   |
| Hemorrhagic cyst descriptors              | Unilocular, no internal vascularity                        |   | May have peripheral flow in wall or surrounding ovarian tissue  |
|   | Reticular pattern  | Fine, thin, intersecting lines  | Represents fibrin strands, not septations   |
|   | Retractile clot  | Avascular component with echogenicity higher than adjacent fluid and angular, straight, or concave margins  |   |
| Dermoid cyst descriptors                  | ≤ 3 locules, no internal vascularity                       |   | May have flow in walls or intervening septa   |
|   | Hyperechoic component (diffuse or regional) with shadowing | Focal hyperechoic component within cystic fluid, or completely hyperechoic lesion, with posterior acoustic shadowing  | Represents fat, cartilage, bone   |
|   | Hyperechoic lines and dots                                 | Bright, linear, and punctate echoes within cystic component   | Represents coiled hair  |
|   | Floating echogenic spherical structures                    | Non-dependent, hyperechoic, round structures within cyst fluid ± posterior acoustic shadowing   | Highly characteristic, albeit uncommon  |
| Endometrioma descriptors                  | ≤ 3 locules, no internal vascularity                       |   | May have flow in walls or intervening septa   |
|   | Homogeneous low-level internal echoes                      | Homogeneous and evenly dispersed echoes throughout entire cyst  | Ground glass echoes = synonym   |
|   | Peripheral punctate echogenic foci                         | Punctate echogenic foci in cyst wall which typically do not shadow, however may demonstrate twinkling artifact  | - Highly characteristic albeit uncommon<br>- Represents hemosiderin byproducts  |
| Septations                                | Complete   | Linear tissue within cyst cavity extending from wall to wall in all planes  |   |
|   | Incomplete   | Linear tissue within cyst cavity not extending from wall to wall in all planes  |   |
| <b>Solid or Solid-Appearing Component</b> |  |   |   |
| Solid component                           |  | Focal wall thickening or solid tissue arising from cyst wall/septation that protrudes into cyst cavity ≥ 3 mm in height   | - Excludes blood products and dermoid cyst contents<br>- May use term <b>solid-appearing</b> if no internal vascularity |
| Papillary projection                      |  | As above and surrounded by fluid on 3 sides   | Number important for risk stratification (< 4 vs. ≥ 4)  |
| <b>Vascularity</b>                        |  |   |   |
| Color Score (CS)                          |  | Numeric overall subjective assessment of lesion vascularity on color or power Doppler<br><br>CS 1 = No flow<br>CS 2 = Minimal flow<br>CS 3 = Moderate flow<br>CS 4 = Very strong flow | - Applies to some cystic and all solid smooth lesions<br>- Does not include flow in surrounding ovarian parenchyma      |
| Peripheral flow                           |  | Circumferential flow on color or power Doppler  | Typical pattern with corpus luteum and hemorrhagic cyst   |
| <b>General and Extra-Ovarian Findings</b> |  |   |   |
| Cysts                                     | Paraovarian cyst   | Simple cyst separate from the adjacent ovary  | - Includes paratubal cyst<br>- Moves independent of ovary with transducer pressure                                      |
|   | Peritoneal inclusion cyst                                  | Fluid collection with ovary at margin or suspended within that conforms to adjacent pelvic organs   | - ± septations representing adhesions<br>- Associated with prior surgery or inflammatory processes                      |

|                    |  |   |   |
|--------------------|--|---|---|
| Hydrosalpinx       | Anechoic, fluid-filled tubular structure | Fluid-distended fallopian tube without internal echoes that has an elongated tubular shape  |   |
|                    | Incomplete septation(s)                  | Internal linear tissue that does not extend from wall to wall in all planes   | Represents folds; may be better appreciated on cine clips           |
|                    | Endosalpingeal folds                     | Short round projections around inner walls of fluid-filled tube often equidistantly spaced  | Represents internal tubal infoldings seen in short axis             |
| Peritoneal Fluid   | Physiologic                              | Confined to pouch of Douglas and below uterine fundus when anteverted/anteflexed or between uterus and urinary bladder when retroverted/retroflexed                   | Considered non-pathologic   |
|                    | Ascites                                  | Fluid extends beyond pouch of Douglas or cul-de-sac and above uterine fundus when anteverted/anteflexed, and anterior/superior to uterus when retroverted/retroflexed | ± internal echoes; more suspicious for malignancy if echoes present |
| Peritoneal nodules |  | Nodularity or focal thickening of the peritoneal lining or along the serosal surface of bowel   | Associated with peritoneal carcinomatosis                           |